QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012,

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 0-17272

TECHNE CORPORATION
(Exact name of registrant as specified in its charter)

Minnesota
(State or other jurisdiction of incorporation or organization)

41-1427402
(I.R.S. Employer Identification No.)

614 McKinley Place N.E.
Minneapolis, MN
(Address of principal executive offices)

55413
(Zip Code)

(612) 379-8854
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2).  Yes ☐ No ☒

At November 2, 2012, 36,828,834 shares of the Company’s Common Stock (par value $0.01) were outstanding.
# Table of Contents

## PART I: FINANCIAL INFORMATION

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 1</td>
<td>Financial Statements (Unaudited)</td>
<td>1</td>
</tr>
<tr>
<td>Condensed Consolidated Statements of Earnings and Comprehensive Income for the Quarters Ended September 30, 2012 and 2011</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Condensed Consolidated Balance Sheets as of September 30, 2012 and June 30, 2012</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Notes to Condensed Consolidated Financial Statements</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

## Item 2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 7 |

## Item 3 | Quantitative and Qualitative Disclosures about Market Risk | 11 |

## Item 4 | Controls and Procedures | 13 |

## PART II: OTHER INFORMATION

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 1</td>
<td>Legal Proceedings</td>
<td>13</td>
</tr>
<tr>
<td>Item 1A</td>
<td>Risk Factors</td>
<td>13</td>
</tr>
<tr>
<td>Item 2</td>
<td>Unregistered Sales of Equity Securities and Use of Proceeds</td>
<td>13</td>
</tr>
<tr>
<td>Item 3</td>
<td>Defaults Upon Senior Securities</td>
<td>13</td>
</tr>
<tr>
<td>Item 4</td>
<td>Mine Safety Disclosures</td>
<td>13</td>
</tr>
<tr>
<td>Item 5</td>
<td>Other Information</td>
<td>14</td>
</tr>
<tr>
<td>Item 6</td>
<td>Exhibits</td>
<td>14</td>
</tr>
</tbody>
</table>

## SIGNATURES | 14 |
## PART I. FINANCIAL INFORMATION

### ITEM 1. FINANCIAL STATEMENTS

**CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME**

**TECHNE Corporation and Subsidiaries**

*(in thousands, except per share data) (unaudited)*

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended September 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2012</td>
</tr>
<tr>
<td><strong>Net sales</strong></td>
<td>$75,025</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>$19,442</td>
</tr>
<tr>
<td><strong>Gross margin</strong></td>
<td>$55,583</td>
</tr>
<tr>
<td><strong>Operating expenses:</strong></td>
<td></td>
</tr>
<tr>
<td>Selling, general and administrative</td>
<td>$10,328</td>
</tr>
<tr>
<td>Research and development</td>
<td>$7,452</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>$17,780</td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td>$37,803</td>
</tr>
<tr>
<td><strong>Other income (expense):</strong></td>
<td></td>
</tr>
<tr>
<td>Interest income</td>
<td>$661</td>
</tr>
<tr>
<td>Other non-operating expense, net</td>
<td>$(478)</td>
</tr>
<tr>
<td><strong>Total other income (expense)</strong></td>
<td>$183</td>
</tr>
<tr>
<td><strong>Earnings before income taxes</strong></td>
<td>$37,986</td>
</tr>
<tr>
<td><strong>Income taxes</strong></td>
<td>$12,318</td>
</tr>
<tr>
<td><strong>Net earnings</strong></td>
<td>$25,668</td>
</tr>
<tr>
<td><strong>Other comprehensive income (loss):</strong></td>
<td></td>
</tr>
<tr>
<td>Foreign currency translation adjustments</td>
<td>$3,925</td>
</tr>
<tr>
<td>Unrealized gains (losses) on available-for-sale investments, net of tax of ($7,589) and ($18), respectively</td>
<td>$(13,559)</td>
</tr>
<tr>
<td><strong>Other comprehensive loss</strong></td>
<td>$(9,634)</td>
</tr>
<tr>
<td><strong>Comprehensive income</strong></td>
<td>$16,034</td>
</tr>
<tr>
<td><strong>Earnings per share:</strong></td>
<td></td>
</tr>
<tr>
<td>Basic</td>
<td>$0.70</td>
</tr>
<tr>
<td>Diluted</td>
<td>$0.70</td>
</tr>
<tr>
<td><strong>Cash dividends per common share:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$0.28</td>
</tr>
<tr>
<td><strong>Weighted average common shares outstanding:</strong></td>
<td></td>
</tr>
<tr>
<td>Basic</td>
<td>36,828</td>
</tr>
<tr>
<td>Diluted</td>
<td>36,895</td>
</tr>
</tbody>
</table>

See Notes to Condensed Consolidated Financial Statements.
## CONDENSED CONSOLIDATED BALANCE SHEETS

**TECHNE Corporation and Subsidiaries**  
*(in thousands, except share and per share data)*

<table>
<thead>
<tr>
<th></th>
<th>September 30, 2012</th>
<th>June 30, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td>(unaudited)</td>
<td></td>
</tr>
<tr>
<td><strong>Current assets:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 130,805</td>
<td>$116,675</td>
</tr>
<tr>
<td>Short-term available-for-sale investments</td>
<td>142,262</td>
<td>152,311</td>
</tr>
<tr>
<td>Trade accounts receivable, less allowance for doubtful accounts of $458 and $455, respectively</td>
<td>35,119</td>
<td>35,668</td>
</tr>
<tr>
<td>Other receivables</td>
<td>1,791</td>
<td>2,073</td>
</tr>
<tr>
<td>Inventories</td>
<td>38,397</td>
<td>38,277</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>1,769</td>
<td>1,503</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td>$350,143</td>
<td>$346,507</td>
</tr>
<tr>
<td>Available-for-sale investments</td>
<td>131,713</td>
<td>143,966</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>94,920</td>
<td>93,788</td>
</tr>
<tr>
<td>Goodwill</td>
<td>86,936</td>
<td>85,682</td>
</tr>
<tr>
<td>Intangible assets, net</td>
<td>46,073</td>
<td>46,476</td>
</tr>
<tr>
<td>Other assets</td>
<td>2,844</td>
<td>2,905</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$712,629</td>
<td>$719,324</td>
</tr>
</tbody>
</table>

| **LIABILITIES AND SHAREHOLDERS’ EQUITY** |         |               |
| **Current liabilities:** |       |               |
| Trade accounts payable | $ 6,541 | $ 6,291 |
| Salaries, wages and related accruals | 4,536        | 4,699       |
| Accrued expenses | 3,101         | 7,275       |
| Income taxes payable | 2,553        | 3,251       |
| Deferred income taxes | 6,170        | 14,234      |
| **Total current liabilities** | $22,901     | $35,750     |
| Deferred income taxes | 9,123        | 9,132       |
| **Shareholders’ equity:** |       |               |
| Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 36,828,834 and 36,826,364, respectively | 368  | 368 |
| Additional paid-in capital | 132,291     | 131,851     |
| Retained earnings | 535,805       | 520,448     |
| Accumulated other comprehensive income | 12,141       | 21,775      |
| **Total shareholders’ equity** | $680,605  | 674,442     |

See Notes to Condensed Consolidated Financial Statements.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  
TECHNE Corporation and Subsidiaries  
(in thousands)  
(unaudited)

<table>
<thead>
<tr>
<th>Quarter Ended September 30</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>CASH FLOWS FROM OPERATING ACTIVITIES:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net earnings</td>
<td>$25,668</td>
<td>$27,521</td>
</tr>
<tr>
<td>Adjustments to reconcile net earnings to net cash provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>3,105</td>
<td>3,135</td>
</tr>
<tr>
<td>Costs recognized on sale of acquired inventory</td>
<td>1,264</td>
<td>2,148</td>
</tr>
<tr>
<td>Deferred income taxes</td>
<td>(777)</td>
<td>(1,066)</td>
</tr>
<tr>
<td>Stock-based compensation expense</td>
<td>303</td>
<td>290</td>
</tr>
<tr>
<td>Excess tax benefit from stock option exercises</td>
<td>(1)</td>
<td>(7)</td>
</tr>
<tr>
<td>Losses by equity method investees</td>
<td>41</td>
<td>198</td>
</tr>
<tr>
<td>Other</td>
<td>107</td>
<td>19</td>
</tr>
<tr>
<td>Change in operating assets and operating liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade accounts and other receivables</td>
<td>1,053</td>
<td>1,591</td>
</tr>
<tr>
<td>Inventories</td>
<td>(1,084)</td>
<td>(226)</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>(252)</td>
<td>(145)</td>
</tr>
<tr>
<td>Trade accounts payable and accrued expenses</td>
<td>218</td>
<td>1,598</td>
</tr>
<tr>
<td>Salaries, wages and related accruals</td>
<td>400</td>
<td>825</td>
</tr>
<tr>
<td>Income taxes payable</td>
<td>(782)</td>
<td>(1,449)</td>
</tr>
<tr>
<td>Net cash provided by operating activities</td>
<td>29,263</td>
<td>34,432</td>
</tr>
<tr>
<td>CASH FLOWS FROM INVESTING ACTIVITIES:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchase of available-for-sale investments</td>
<td>(21,119)</td>
<td>(44,311)</td>
</tr>
<tr>
<td>Proceeds from sales of available-for-sale investments</td>
<td>6,200</td>
<td>10,195</td>
</tr>
<tr>
<td>Proceeds from maturities of available-for-sale investments</td>
<td>11,601</td>
<td>24,763</td>
</tr>
<tr>
<td>Increase in other long-term assets</td>
<td>(87)</td>
<td>0</td>
</tr>
<tr>
<td>Additions to property and equipment</td>
<td>(2,515)</td>
<td>(1,096)</td>
</tr>
<tr>
<td>Net cash used in investing activities</td>
<td>(5,920)</td>
<td>(10,449)</td>
</tr>
<tr>
<td>CASH FLOWS FROM FINANCING ACTIVITIES:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash dividends</td>
<td>(10,312)</td>
<td>(10,026)</td>
</tr>
<tr>
<td>Proceeds from stock option exercises</td>
<td>136</td>
<td>45</td>
</tr>
<tr>
<td>Excess tax benefit from stock option exercises</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>Purchase of common stock for stock bonus plans</td>
<td>(573)</td>
<td>(907)</td>
</tr>
<tr>
<td>Repurchase of common stock</td>
<td>0</td>
<td>(10,675)</td>
</tr>
<tr>
<td>Net cash used in financing activities</td>
<td>(10,748)</td>
<td>(21,556)</td>
</tr>
<tr>
<td>Effect of exchange rate changes on cash and cash equivalents</td>
<td>1,535</td>
<td>(805)</td>
</tr>
<tr>
<td>Net increase in cash and cash equivalents</td>
<td>14,130</td>
<td>1,622</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of period</td>
<td>116,675</td>
<td>77,613</td>
</tr>
<tr>
<td>Cash and cash equivalents at end of period</td>
<td>$130,805</td>
<td>$79,235</td>
</tr>
</tbody>
</table>

See Notes to Condensed Consolidated Financial Statements.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

TECHNE Corporation and Subsidiaries
(unaudited)

A. Basis of presentation:
The interim unaudited condensed consolidated financial statements of Techne Corporation and Subsidiaries (the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying interim unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature.

A summary of significant accounting policies followed by the Company is detailed in the Company’s Annual Report on Form 10-K for fiscal 2012. The Company follows these policies in preparation of the interim unaudited condensed consolidated financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2012, included in the Company’s Annual Report on Form 10-K for fiscal 2012.

B. Available-for-sale investments:
The Company’s available-for-sale investments at September 30, 2012 and June 30, 2012 are carried at fair value and are valued using quoted market prices in active markets (Level 1 input) for identical assets and liabilities.

C. Inventories:
Inventories consist of (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>September 30, 2012</th>
<th>June 30, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raw materials</td>
<td>$5,814</td>
<td>$5,678</td>
</tr>
<tr>
<td>Finished goods</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>32,583</td>
<td>32,599</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$38,397</td>
<td>$38,277</td>
</tr>
</tbody>
</table>

D. Property and equipment:
Property and equipment consist of (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>September 30, 2012</th>
<th>June 30, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Land</td>
<td>$7,505</td>
<td>$7,473</td>
</tr>
<tr>
<td>Buildings and improvements</td>
<td>125,783</td>
<td>123,257</td>
</tr>
<tr>
<td>Laboratory equipment</td>
<td>32,044</td>
<td>31,658</td>
</tr>
<tr>
<td>Office equipment</td>
<td>$5,823</td>
<td>5,710</td>
</tr>
<tr>
<td></td>
<td>171,155</td>
<td>168,098</td>
</tr>
<tr>
<td>Accumulated depreciation and amortization</td>
<td>(76,235)</td>
<td>(74,310)</td>
</tr>
<tr>
<td></td>
<td>$94,920</td>
<td>$93,788</td>
</tr>
</tbody>
</table>
E. Intangible assets and goodwill:

Intangible assets consist of (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>September 30, 2012</th>
<th>June 30, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Developed technology</td>
<td>$30,112</td>
<td>$29,410</td>
</tr>
<tr>
<td>Trade names</td>
<td>18,069</td>
<td>17,871</td>
</tr>
<tr>
<td>Customer relationships</td>
<td>8,804</td>
<td>8,712</td>
</tr>
<tr>
<td>Non-compete agreement</td>
<td>400</td>
<td>400</td>
</tr>
<tr>
<td></td>
<td>57,385</td>
<td>56,393</td>
</tr>
<tr>
<td>Accumulated amortization</td>
<td>(11,312)</td>
<td>(9,917)</td>
</tr>
<tr>
<td></td>
<td>$46,073</td>
<td>$46,476</td>
</tr>
</tbody>
</table>

The change in the carrying amount of net intangible assets for the quarter ended September 30, 2012 resulted from amortization expense and currency translation. Amortization expense related to technologies included in cost of sales was $753,000 and $764,000, respectively, for the quarters ended September 30, 2012 and 2011. Amortization expense related to trade names, customer relationships, and the non-compete agreement included in selling, general and administrative expense was $519,000 and $521,000 for the quarters ended September 30, 2012 and 2011, respectively.

The change in the carrying amount of goodwill for the quarter ended September 30, 2012 resulted from currency translation.

F. Share-based compensation:

Option activity under the Company’s stock option plans during the quarter ended September 30, 2012 was as follows:

<table>
<thead>
<tr>
<th></th>
<th>Shares (in thousands)</th>
<th>Weighted Average Exercise Price</th>
<th>Weighted Average Contractual Life (Yrs.)</th>
<th>Aggregate Intrinsic Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outstanding at June 30, 2012</td>
<td>575</td>
<td>$65.78</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Granted</td>
<td>5</td>
<td>$74.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercised</td>
<td>(2)</td>
<td>$55.11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outstanding at September 30, 2012</td>
<td>578</td>
<td>$65.90</td>
<td>5.5</td>
<td>$4.1 million</td>
</tr>
<tr>
<td>Exercisable at September 30, 2012</td>
<td>405</td>
<td>$62.84</td>
<td>5.5</td>
<td>$3.9 million</td>
</tr>
</tbody>
</table>

The fair value of options granted under the Company’s stock option plans was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used:

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended September 30, 2012</th>
<th>Quarter Ended September 30, 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dividend yield</td>
<td>1.5%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Expected annualized volatility</td>
<td>23%</td>
<td>23%</td>
</tr>
<tr>
<td>Risk free interest rate</td>
<td>0.5%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Expected life</td>
<td>4 years</td>
<td>4 years</td>
</tr>
</tbody>
</table>

The dividend yield is based on the Company’s historical annual cash dividend divided by the market value of the Company’s Common Stock. The expected annualized volatility is based on the Company’s historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted. Separate groups of employees that have similar historical exercise behavior with regard to option exercise timing and forfeiture rates are considered separately in determining option fair value.
The weighted average per share fair value of options granted during the quarters ended September 30, 2012 and 2011 was $11.85 and $13.66, respectively. The total intrinsic value of options exercised during the quarters ended September 30, 2012 and 2011 was $40,000 and $34,000, respectively. The total fair value of options vested during the quarters ended September 30, 2012 and 2011 was $55,000 and $71,000, respectively.

Stock-based compensation cost of $303,000 and $290,000 was included in selling, general and administrative expense for the quarters ended September 30, 2012 and 2011, respectively. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. As of September 30, 2012, there was $1.9 million of total unrecognized compensation cost related to non-vested stock options. The weighted average period over which the compensation cost is expected to be recognized is 1.1 years.

G. Earnings per share:
Shares used in the earnings per share computations are as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended September 30, 2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weighted average common shares outstanding-basic</td>
<td>36,828</td>
<td>37,095</td>
</tr>
<tr>
<td>Dilutive effect of stock options</td>
<td>67</td>
<td>75</td>
</tr>
<tr>
<td>Weighted average common shares outstanding-diluted</td>
<td>36,895</td>
<td>37,170</td>
</tr>
</tbody>
</table>

The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 199,000 and 170,000 for the quarters ended September 30, 2012 and 2011, respectively.

H. Segment information:
The Company has two reportable segments based on the nature of products: biotechnology and hematology. Following is financial information relating to the Company’s reportable segments (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended September 30, 2012</th>
<th>2011</th>
</tr>
</thead>
</table>
| External sales
  Biotechnology      | $69,503                          | $72,303 |
  Hematology           | 5,522                           | 5,293 |
| Consolidated net sales | $75,025                         | $77,596 |
| Earnings before income taxes
  Biotechnology      | $36,994                          | $39,984 |
  Hematology           | 2,103                           | 1,918 |
| Segment earnings before income taxes | 39,097                           | 41,902 |
| Unallocated corporate expenses and equity method investee losses | (1,111)                           | (1,402) |
| Consolidated earnings before income taxes | $37,986                          | $40,500 |

I. Accumulated other comprehensive income:
Accumulated other comprehensive income consists of (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>September 30, 2012</th>
<th>June 30, 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreign currency translation adjustments</td>
<td>$(16,818)</td>
<td>$(20,743)</td>
</tr>
<tr>
<td>Net unrealized gain on available-for-sale investments, net of tax</td>
<td>28,959</td>
<td>42,518</td>
</tr>
<tr>
<td></td>
<td>$12,141</td>
<td>$21,775</td>
</tr>
</tbody>
</table>
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

TECHNE Corporation and subsidiaries (the Company) are engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. These activities are conducted domestically through TECHNE Corporation’s wholly-owned subsidiaries, Research and Diagnostic Systems, Inc. (R&D Systems), Boston Biochem, Inc. (Boston Biochem), and BiosPacific, Inc. (BiosPacific). TECHNE Corporation’s European biotechnology operations are conducted through its wholly-owned U.K. subsidiaries, R&D Systems Europe Ltd. (R&D Europe) and Tocris Holdings Limited (Tocris). R&D Europe has a sales subsidiary, R&D Systems GmbH, in Germany and a sales office in France. TECHNE Corporation distributes its biotechnology products in China through its wholly-owned subsidiary, R&D Systems China Co., Ltd. (R&D China). R&D China has a sales subsidiary, R&D Systems Hong Kong Ltd., in Hong Kong.

The Company has two reportable segments based on the nature of its products: biotechnology and hematology. R&D Systems’ Biotechnology Division, R&D Europe, Tocris, R&D China, BiosPacific and Boston Biochem operating segments are included in the biotechnology reporting segment. The Company’s biotechnology reporting segment develops, manufactures and sells biotechnology research and diagnostic products world-wide. The Company’s hematology reporting segment, which consists of R&D Systems’ Hematology Division, develops and manufactures hematology controls and calibrators for sale world-wide.

RESULTS OF OPERATIONS

Consolidated net sales and consolidated net earnings decreased 3.3% and 6.7%, respectively for the quarter ended September 30, 2012 compared to the quarter ended September 30, 2011. Consolidated net sales and consolidated net earnings for the quarter ended September 30, 2012 were unfavorably affected by changes in exchange rates from the same prior-year period. A stronger U.S. dollar as compared to foreign currencies reduced sales by $1.9 million in the quarter ended September 30, 2012 from the comparable prior-year period.

Net sales

Consolidated net sales for the quarter ended September 30, 2012 were $75.0 million, a decrease of $2.6 million (3.3%) from the quarter ended September 30, 2011. Excluding the effect of the change from the comparable prior-year period in exchange rates used to convert sales in foreign currencies (primarily British pound sterling, euros and Chinese yuan), consolidated net sales for the quarter ended September 30, 2012 decreased 0.9% from the quarter ended September 30, 2011. Included in consolidated net sales for the quarter ended September 30, 2012 was $288,000 of sales of new biotechnology products that had their first sale in fiscal 2013.

Net sales by reportable segment were as follows (in thousands):

<table>
<thead>
<tr>
<th>Segment</th>
<th>Quarter Ended September 30, 2012</th>
<th>Quarter Ended September 30, 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biotechnology</td>
<td>$69,503</td>
<td>$72,303</td>
</tr>
<tr>
<td>Hematology</td>
<td>5,522</td>
<td>5,293</td>
</tr>
<tr>
<td>Consolidated net sales</td>
<td>$75,025</td>
<td>$77,596</td>
</tr>
</tbody>
</table>

Biotechnology segment net sales decreased $2.8 million (3.9%) for the quarter ended September 30, 2012 compared to the same prior-year period. This decrease resulted primarily from changes in exchange rates from the comparable prior-year period which impacted sales by $1.9 million, as noted above. The quarter ended September 30, 2012 also had one less selling day as compared to the same prior-year period.
Biotechnology segment sales growth (decline), excluding the effect of changes in exchange rates, from the same prior-year periods were as follows:

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended September 30</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. industrial, pharmaceutical and biotechnology</td>
<td>(5.0%)</td>
<td>9.3%</td>
<td></td>
</tr>
<tr>
<td>U.S. academic</td>
<td>(4.0%)</td>
<td>(2.5%)</td>
<td></td>
</tr>
<tr>
<td>Europe</td>
<td>3.1%</td>
<td>(0.7%)</td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>25.1%</td>
<td>14.1%</td>
<td></td>
</tr>
<tr>
<td>Pacific rim distributors, excluding China</td>
<td>Unchanged</td>
<td>Unchanged</td>
<td></td>
</tr>
</tbody>
</table>

Biotechnology segment net sales consisted of the following:

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended September 30</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Industrial, pharmaceutical and biotechnology</td>
<td>30%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Academic</td>
<td>14%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>13%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>57%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Europe</td>
<td>27%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pacific rim distributors, excluding China</td>
<td>9%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rest of world</td>
<td>3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>100%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Hematology segment net sales increased $229,000 (4.3%) for the quarter ended September 30, 2012 compared to the same prior-year period as a result of increased sales volume.

**Gross margins**

Segment gross margins, as a percentage of net sales, were as follows:

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended September 30</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biotechnology</td>
<td>76.1%</td>
<td>77.2%</td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td>48.5%</td>
<td>48.2%</td>
<td></td>
</tr>
<tr>
<td>Consolidated</td>
<td>74.1%</td>
<td>75.2%</td>
<td></td>
</tr>
</tbody>
</table>

Biotechnology segment gross margin percentages for the quarter ended September 30, 2012 decreased from the same prior-year period primarily due to lower sales caused by unfavorable exchange rates. This negative gross margin impact was partially offset by a decline in the costs recognized upon the sale of inventory acquired in fiscal 2011 which was written-up to fair value. Hematology segment gross margin percentage for the quarter ended September 30, 2012 increased slightly from the comparable prior-year period as a result of changes in product mix.
Selling, general and administrative expenses
Selling, general and administrative expenses for the quarter ended September 30, 2012 decreased $445,000 (4.1%) from the same prior-year period. The decrease in selling, general and administrative expense resulted from a decrease in profit sharing expense of $685,000 from the comparable prior-year quarter.

Consolidated selling, general and administrative expenses were composed of the following (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended September 30,</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2012</td>
<td>2011</td>
<td></td>
</tr>
<tr>
<td>Biotechnology</td>
<td>$ 9,140</td>
<td>$ 9,470</td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td>419</td>
<td>480</td>
<td></td>
</tr>
<tr>
<td>Unallocated corporate expenses</td>
<td>769</td>
<td>823</td>
<td></td>
</tr>
<tr>
<td>Consolidated selling, general and administrative expenses</td>
<td>$10,328</td>
<td>$10,773</td>
<td></td>
</tr>
</tbody>
</table>

Research and development expenses
Research and development expenses were composed of the following (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended September 30,</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2012</td>
<td>2011</td>
<td></td>
</tr>
<tr>
<td>Biotechnology</td>
<td>$7,259</td>
<td>$6,469</td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td>193</td>
<td>198</td>
<td></td>
</tr>
<tr>
<td>Consolidated research and development expenses</td>
<td>$7,452</td>
<td>$6,667</td>
<td></td>
</tr>
</tbody>
</table>

Research and development expenses for the quarter ended September 30, 2012 increased $785,000 (11.8%) from the same prior-year period. The increase was mainly due to increases in personnel and supply costs associated with the ongoing development and release of new high-quality biotechnology products.

Other non-operating expense, net
Other non-operating expense, net, consists mainly of foreign currency transaction gains and losses, rental income, building expenses related to rental property, and the Company’s share of losses by equity method investees. Amounts were as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended September 30,</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2012</td>
<td>2011</td>
<td></td>
</tr>
<tr>
<td>Foreign currency gains (losses)</td>
<td>($78)</td>
<td>$(524)</td>
<td></td>
</tr>
<tr>
<td>Rental income</td>
<td>170</td>
<td>134</td>
<td></td>
</tr>
<tr>
<td>Building expenses related to rental property</td>
<td>(529)</td>
<td>(587)</td>
<td></td>
</tr>
<tr>
<td>Losses by equity method investees</td>
<td>(41)</td>
<td>(198)</td>
<td></td>
</tr>
<tr>
<td>Other non-operating expense, net</td>
<td>$(478)</td>
<td>$(1,175)</td>
<td></td>
</tr>
</tbody>
</table>

9
LIQUIDITY AND CAPITAL RESOURCES

At September 30, 2012, cash and cash equivalents and available-for-sale investments were $405 million compared to $413 million at June 30, 2012. Included in available-for-sale-investments at September 30, 2012 was the fair value of the Company’s investment in ChemoCentryx, Inc. (CCXI) of $73.5 million. The fair value of the Company’s CCXI investment at June 30, 2012 was $94.7 million.

At September 30, 2012, approximately 61%, 36%, and 3% of the Company’s cash and cash equivalents of $131 million are located in the U.S., United Kingdom and China, respectively. At September 30, 2012, approximately 96% of the Company’s available-for-sale investment accounts are located in the U.S., with the remaining 4% in China. The Company has either paid U.S. income taxes on its undistributed foreign earnings or intends to indefinitely reinvest the undistributed earnings in the foreign operations.

The Company believes it can meet its cash and working capital requirements, facility expansion and capital addition needs and share repurchase, cash dividend, investment and acquisition strategies for at least the next twelve months through currently available funds, cash generated from operations and maturities or sales of available-for-sale investments.

Cash flows from operating activities

The Company generated cash of $29.3 million from operating activities in the first quarter of fiscal 2013 compared to $34.4 million in the first quarter of fiscal 2012. The decrease from the prior year was primarily due to decreased net earnings for the quarter and changes in receivable and accounts payable and income taxes payable as a result of the timing of receipts and payments.

Cash flows from investing activities

During the quarter ended September 30, 2012, the Company purchased $21.1 million and had sales or maturities of $17.8 million of available-for-sale investments. During the quarter ended September 30, 2011, the Company purchased $44.3 million and had sales or maturities of $35.0 million of available-for-sale investments. The Company’s investment policy is to place excess cash in municipal and corporate bonds and other investments with maturities of less than three years. The objective of this policy is to obtain the highest possible return while minimizing risk and keeping the funds accessible.

Capital expenditures for fixed assets for the first quarter of fiscal 2013 and 2012 were $2.5 million and $1.1 million, respectively. Included in capital expenditures for the first quarters of fiscal 2013 and 2012 was $2.0 million and $663,000, respectively, related to expansion and remodeling of office and laboratory space at the Company’s Minneapolis facility. The remaining capital additions were mainly for laboratory and computer equipment. Capital expenditures in the remainder of fiscal 2013 are expected to be approximately $26.2 million including $20 million related to expansion space in Minneapolis and the purchase of land and construction of a new facility in the United Kingdom, both of which are not expected to be completed until fiscal 2014. Capital expenditures are expected to be financed through currently available funds and cash generated from operating activities.

Cash flows from financing activities

During the first quarter of fiscal 2013 and 2012, the Company paid cash dividends of $10.3 million and $10.0 million, respectively, to all common shareholders. On October 25, 2012, the Company announced the payment of a $0.30 per share cash dividend. The dividend of approximately $11.0 million will be payable November 19, 2012 to all common shareholders of record on November 5, 2012.

Cash of $136,000 and $45,000 was received during the quarters ended September 30, 2012 and 2011, respectively, from the exercise of stock options. The Company also recognized excess tax benefits from stock option exercises of $1,000 and $7,000 for the quarter ended September 30, 2012 and 2011, respectively.

During the first quarter of fiscal 2013 and 2012, the Company repurchased 8,324 and 13,140 shares of common stock for its employee stock bonus plans at a cost of $573,000 and $907,000, respectively.
During the first quarter of fiscal 2012, the Company repurchased and retired 149,860 shares of common stock at a market value of $10.7 million. The Company did not repurchase any shares during the first quarter of fiscal 2013.

CONTRACTUAL OBLIGATIONS
There were no material changes outside the ordinary course of business in the Company’s contractual obligations during the quarter ended September 30, 2012.

CRITICAL ACCOUNTING POLICIES
The Company’s significant accounting policies are discussed in the Company’s Annual Report on Form 10-K for fiscal 2012 and are incorporated herein by reference. The application of certain of these policies requires judgments and estimates that can affect the results of operations and financial position of the Company. Judgments and estimates are used for, but not limited to, valuation of available-for-sale investments, inventory valuation and allowances, valuation of intangible assets and goodwill and valuation of investments in unconsolidated entities. There have been no significant changes in estimates in fiscal 2013 that would require disclosure. There have been no changes to the Company’s policies in fiscal 2013.

FORWARD LOOKING INFORMATION AND CAUTIONARY STATEMENTS
This quarterly report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include those regarding the Company’s expectations as to the effect of changes to accounting policies, the amount of capital expenditures for the remainder of the fiscal year, the timeframe for completing facility improvements in the U.S. and the U.K., the source of funding for capital expenditure requirements, the sufficiency of currently available funds for meeting the Company’s needs, and the impact of fluctuations in foreign currency exchange rates. These statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company’s actual results: the introduction and acceptance of new products, general economic conditions, increased competition, the reliance on internal manufacturing and related operations, the impact of currency exchange rate fluctuations, economic instability in Eurozone countries, the recruitment and retention of qualified personnel, the impact of governmental regulation, maintenance of intellectual property rights, credit risk and fluctuation in the market value of the Company’s investment portfolio, unforeseen delays and expenses related to facility improvements and the success of financing efforts by companies in which the Company has invested. For additional information concerning such factors, see the Company’s Annual Report on Form 10-K for fiscal 2012 as filed with the Securities and Exchange Commission.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
At September 30, 2012, the Company had a portfolio of fixed income debt securities, excluding those classified as cash and cash equivalents, of $201 million. These securities, like all fixed income instruments, are subject to interest rate risk and will decline in value if market interest rates increase. As the Company’s fixed income securities are classified as available-for-sale, no gains or losses are recognized by the Company in its consolidated statements of earnings due to changes in interest rates unless such securities are sold prior to maturity. The Company generally holds its fixed income securities until maturity and, historically, has not recorded any material gains or losses on any sale prior to maturity.

At September 30, 2012, the Company held an investment in the common stock of CCXI. The investment was included in short-term available-for-sale investments at its fair value of $73.5 million. At September 30, 2012, the potential loss in fair value due to a 10% decrease in the market value of CCXI was $7.4 million.
The Company operates internationally, and thus is subject to potentially adverse movements in foreign currency exchange rates. For the quarter ended September 30, 2012, approximately 29% of consolidated net sales were made in foreign currencies, including 13% in euros, 7% in British pound sterling, 4% in Chinese yuan and the remaining 5% in other European currencies. As a result, the Company is exposed to market risk mainly from foreign exchange rate fluctuations of the euro, British pound sterling and the Chinese yuan as compared to the U.S. dollar as the financial position and operating results of the Company’s foreign operations are translated into U.S. dollars for consolidation.

Month-end average exchange rates between the British pound sterling, euro and Chinese yuan and the U.S. dollar, which have not been weighted for actual sales volume in the applicable months in the periods, were as follows:

<table>
<thead>
<tr>
<th>Denominated Currency</th>
<th>Quarter Ended September 30, 2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Euro</td>
<td>1.26</td>
<td>1.41</td>
</tr>
<tr>
<td>British pound sterling</td>
<td>1.59</td>
<td>1.61</td>
</tr>
<tr>
<td>Chinese yuan</td>
<td>.158</td>
<td>.156</td>
</tr>
</tbody>
</table>

The Company’s exposure to foreign exchange rate fluctuations also arises from trade receivables and intercompany payables denominated in one currency in the financial statements, but receivable or payable in another currency. At September 30, 2012, the Company had the following trade receivable and intercompany payables denominated in one currency but receivable or payable in another currency (in thousands):

<table>
<thead>
<tr>
<th>Denominated Currency</th>
<th>U.S. Dollar Equivalent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts receivable in:</td>
<td></td>
</tr>
<tr>
<td>Euros</td>
<td>932</td>
</tr>
<tr>
<td>Other European currencies</td>
<td>919</td>
</tr>
<tr>
<td>Intercompany payable in:</td>
<td></td>
</tr>
<tr>
<td>Euros</td>
<td>290</td>
</tr>
<tr>
<td>U.S. dollars</td>
<td>2,422</td>
</tr>
<tr>
<td>U.S. dollars yuan</td>
<td>4,448</td>
</tr>
</tbody>
</table>

All of the above balances are revolving in nature and are not deemed to be long-term balances. The Company does not enter into foreign exchange forward contracts to reduce its exposure to foreign currency rate changes on forecasted intercompany foreign currency denominated balance sheet positions. Foreign currency transaction gains and losses are included in “Other non-operating expense” in the Consolidated Statement of Earnings and Comprehensive Income. The effect of translating net assets of foreign subsidiaries into U.S. dollars are recorded on the Consolidated Balance Sheet as part of “Accumulated other comprehensive income.”

The effects of a hypothetical simultaneous 10% appreciation in the U.S. dollar from September 30, 2012 levels against the euro, British pound sterling and Chinese yuan are as follows (in thousands):

- Decrease in translation of 2013 earnings into U.S. dollars (annualized) $2,143
- Decrease in translation of net assets of foreign subsidiaries 15,667
- Additional transaction losses 462
ITEM 4. CONTROLS AND PROCEDURES

As of the end of the period covered by this report, the Company conducted an evaluation, under the supervision and with the participation of the principal executive officer and principal financial officer, of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 as amended (the Exchange Act)). Based on this evaluation, the principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures are effective to ensure that material information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. There was no change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the Company’s most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

As of November 9, 2012, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company’s business, results of operations, financial condition or cash flows.

ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors previously disclosed in Part I, Item 1A, “Risk Factors,” of the Company’s Annual Report on Form 10-K for the year ended June 30, 2012.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table sets forth the repurchases of Company common stock for the quarter ended September 30, 2012:

<table>
<thead>
<tr>
<th>Period</th>
<th>Total Number of Shares Purchased</th>
<th>Average Price Paid Per Share</th>
<th>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</th>
<th>Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/1/12-7/31/12</td>
<td>0</td>
<td>$ 0</td>
<td>0</td>
<td>$ 27.0 million</td>
</tr>
<tr>
<td>8/1/12-8/31/12</td>
<td>8,324</td>
<td>$ 68.89</td>
<td>0</td>
<td>$ 27.0 million</td>
</tr>
<tr>
<td>9/1/12-9/30/12</td>
<td>0</td>
<td>$ 0</td>
<td>0</td>
<td>$ 27.0 million</td>
</tr>
<tr>
<td>Total</td>
<td>8,324</td>
<td>$ 68.89</td>
<td>0</td>
<td>$ 27.0 million</td>
</tr>
</tbody>
</table>

In April 2009, the Company authorized a plan for the repurchase and retirement of $60 million of its common stock. The plan does not have an expiration date. In October 2012, the Company increased the amount authorized under the plan by $100 million.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.
ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

See “exhibit index” following the signature page.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TECHNE CORPORATION
(Company)

Date: November 9, 2012
/s/ Thomas E. Oland
Thomas E. Oland
President, Chief Executive Officer

Date: November 9, 2012
/s/ Gregory J. Melsen
Gregory J. Melsen
Chief Financial Officer

EXHIBIT INDEX
TO
FORM 10-Q

TECHNE CORPORATION

<table>
<thead>
<tr>
<th>Exhibit #</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>31.1</td>
<td>Section 302 Certification</td>
</tr>
<tr>
<td>31.2</td>
<td>Section 302 Certification</td>
</tr>
<tr>
<td>32.1</td>
<td>Section 906 Certification</td>
</tr>
<tr>
<td>32.2</td>
<td>Section 906 Certification</td>
</tr>
<tr>
<td>101</td>
<td>The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Earnings and Comprehensive Income, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv) Notes to the Condensed Consolidated Financial Statements.</td>
</tr>
</tbody>
</table>
CERTIFICATION

I, Thomas E. Oland, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Techne Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

   a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

   b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

   d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

   a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

   b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2012

/s/ Thomas E. Oland
Thomas E. Oland
Chief Executive Officer
CERTIFICATION

1. Gregory J. Melsen, certify that:
   1. I have reviewed this quarterly report on Form 10-Q of Techne Corporation;
   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
   4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
      a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
      b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
      c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
      d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
   5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):
      a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
      b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2012

/s/ Gregory J. Melsen
Gregory J. Melsen
Chief Financial Officer
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Techne Corporation (the “Company”) On Form 10-Q for the quarter ended September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas E. Oland, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Thomas E. Oland
Chief Executive Officer

November 9, 2012
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Techne Corporation (the “Company”) On Form 10-Q for the quarter ended September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gregory J. Melsen, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Gregory J. Melsen
Chief Financial Officer
November 9, 2012